For instance, the use of sodium-glucose cotransporter 2(SGLT2) inhibitors has shown promise in enhancing autophagic activity andimproving heart failure outcomes by targeting metabolic pathways that intersectwith autophagy. Here, SLC5A2 is linked to heart failure.